We found that circNfix could attenuate Ang II–induced cardiac hypertrophy in vitro and TAC-induced cardiac hypertrophy in vivo by regulating the miR-145-5p/activating transcription factor 3 (ATF3) axis. This evidence concerns the gene ATF3 and persistent truncus arteriosus.